Jump to Main Content

FDA Alerts

FDA Approves Luspatercept-aamt for Anemia in Patients with Beta Thalassemia

The Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corp.) for treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
Citations